The physiology of amylin and insulin: Maintaining the balance between glucose secretion and glucose uptake

Diabetes Educator

Volumn 32, Issue SUPPL. 3, 2006, Pages

  Martin, Catherine ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID; GLUCAGON; GLUCOSE; INSULIN; PRAMLINTIDE;

ARTICLE; BIOLOGICAL MODEL; HOMEOSTASIS; HUMAN; METABOLISM; PHYSIOLOGY;

AMYLOID; GLUCAGON; GLUCOSE; HOMEOSTASIS; HUMANS; INSULIN; MODELS, BIOLOGICAL;

EID: 33646734850     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721706288237     Document Type: Article

References (13)

1. Pehling G, Tessari P, Gerich JE, Raymond MW, Service FJ, Rizza RA. Abnormal meal carbohydrate disposition in insulin-dependent diabetes: relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy. J Clin Invest. 1984;74:985-991.
2. th ed. Philadelphia, Pa: W. B. Saunders; 1992:1255-1333.
3. Kruger DF, Gatcomb PM, Owen SK. Clinical implications of amylin and amylin deficiency. Diabetes Educ. 1999;25:389-397.
4. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des. 2001;7:1353-1373.
5. Unger RH. Glucagon physiology and pathophysiology. N Engl J Med. 1971;285:443-449.
6. Wahren J, Felig P, Hagenfeldt L. Effect of protein ingestion on splanchnic and leg metabolism in normal man and in patients with diabetes mellitus. J Clin Invest. 1976;57:987-999.
7. Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology. 1995;109:755-765.
8. Fineman MS, Koda JE, Shen LZ, et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism. 2002;51:636-641.
9. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res. 2002;34:504-508.
10. Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care. 2001;24:371-381.
11. Kong MF, Stubbs TA, King P, et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia. 1998;41:577-583.
12. Kolterman OG, Schwartz S, Corder C, et al. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia. 1996;39:492-499.
13. Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabet Med. 1997;14:547-555.